Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3

This publication has 37 references indexed in Scilit:

• Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
  Gastroenterology, 2005
• Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
  New England Journal of Medicine, 2005
• International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
  Published by Elsevier ,2005
• Comparison of a 6‐month course peginterferon α‐2b plus ribavirin and interferon α‐2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
  Journal of Viral Hepatitis, 2005
• Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2
  Journal of Hepatology, 2004
• Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
  Annals of Internal Medicine, 2004
• High Body Mass Index Is An Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C
  Hepatology, 2003
• Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
  Journal of Hepatology, 2002
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001